AMRI Acquires Whitehouse Laboratories

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-01-06-2016
Volume 12
Issue 1

AMRI adds analytical capabilities to its outsourcing services offerings with the acquisition of Whitehouse Labs.

Albany Molecular Research Inc. (AMRI) announced on Dec. 15, 2015, that it has acquired all the outstanding equity interests of Whitehouse Laboratories for $54 million in cash, and an additional $2 million in shares of AMRI common stock contingent upon Whitehouse Labs achieving certain 2015 targets.

Whitehouse Labs, based in Lebanon, NJ, offers testing solutions for life sciences including materials and excipients, container qualification and container closure integrity testing, analytical chemistry, drug delivery systems and device qualification programs, packaging, distribution, and stability and storage programs.

In a statement announcing the acquisition, William S. Marth, AMRI's president and chief executive officer noted that Whitehouse Labs’ service offerings meet the needs of its customers and will augment the company’s discovery, development, and manufacturing services.

Source: Albany Molecular Research Inc. (AMRI)

 

 

Recent Videos
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content